Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2026-06-07 @ 7:30 AM
Study NCT ID:
NCT05604560
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-23
First Post:
2022-10-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Sponsor:
Lei Zheng
Organization:
Study Overview
Official Title:
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| STUDY00001055 | OTHER | University of Texas Health Science Center at San Antonio IRB | View |